PLATBIO
Developing new drug using a novel drug discovery platform
with sustainable growth strategy
OUR MISSION
1. Our mission is to lead novel drug development program by innovative and revolutionary platform.
2. We dedicate ourselves to establishment of straightforward translational R&D strategy for non-clinical and clinical program
3. With our proprietary translational research capability and new drug screening platforms, we innovate the new drug development and lead in overcoming the illness.
Established in October, 2018
Developing new drug using
a novel drug discovery platform
with sustainable growth strategy
CHAIRMAN
Scientific Founder
Sun Jin Kim
M.D., Ph.D
Former / Executive Vice President, CMO, Executive Director of Research Center, Hanmi Pharmaceutical Co., Ltd
Former / Professor, Cancer Biology, Clinical Translational & Metastasis Research Center, The University of Texas, MD Anderson Cancer Center
Former / Invited Scientist of National Cancer Center Research Institute, Tokyo, Japan
Postgraduate School, Seoul National University
College of Medicine, Seoul National University
College of Natural Science, Seoul National University
GLOBAL LEADER
HONORS AND AWARDS
[Scholar in Training Award]
American Association for Cancer Research l 2002
[Bristol-Myers Squibb Award in Clinical Translation Research]
Bristol-Myers Squibb l 2002
[Scholar in Training Award]
American Association for Cancer Research l 2001
[Bristol-Myers Squibb Award in Clinical Translation Research]
Bristol-Myers Squibb l 2001
[The Best Achievement of the Year]
Korean Urologic Cancer Association l 1998
CHIEF INSTRUCTOR
NCI-sponsored orthotopic animal model training program
ORTHOTOPIC ANIMAL MODEL
TUMOR ‘TARGET’
The growth and spread of a tumor involves the cancer cells themselves as well as the environment around them. Crosstalk of tumor and organ microenvironment should be considered for the establishment of right tumor models for the pre-clinical research and evaluation of anti-cancer drugs. Orthotopic tumor models are powerful tools for mimicking the interaction between tumor and organ microenvironment. The organ-specific microenvironment induces tumor growth and specific signatures similar to that of the original tumor.
UNMET NEEDS
1. Limitation in target excavation from discrepancy between preclinical (laboratory) and clinical reality
- Despite of efforts to hasten the process of drug development using innovative technologies, the current efforts still remain to be low in cost effectiveness.
2. Tremendous increase in development cost
- Cost to develop new pharmaceutical drug now exceeds $2.5b
- A benchmark report estimates that the cost of bringing a drug to market has more than doubled in the past 10 years
3. Increase of difficulties in developmental process
- Complexed regimens: change of analogue concept to digital precision medicine
Proposed solution to overcome unmet needs with
New approach with genomics and proteomics driven platform
Platform for Revolutionary Identification & Isolation of Novel Targets, PRIINT™
Cross-species hybridization of microarray experiment (CHME)
RNA
Custom antibody array with experimental sera from mice
IHC analyses with experimental tissues from mice
Patients
tissues & sera
1. Establishment of precise orthotopic animal models
2. Revolutionary identification & isolation of novel targets with tissues from orthotopic animal models by bioinformatics
3. Cross-validation of tumor targets in the experimental animal tissues and human sera/surgical specimens
Confirmed list of novel targets in pancreatic and ovarian cancers;
Expansion to various solid tumors
Confirmed up-regulated protein encoding genes in cancers & application
Protein Characterization
Pathway/Interaction, Class, Localization, Function…
Approach
Monitoring Markers
Therapeutic
Targets
Screening Markers
CRO / Consultation
Evaluation of efficacy by
orthotopic animal models
Leading drug repositioning
Development of therapeutic regimensincluding combination therapies
CRO/Consultation for nonclinical and clinical development
ORTHOTOPIC /
METASTASIS ANIMAL MODEL
Brain
Model
Prostate
Model
Pancreas
Model
Ovary
Model
Ear
Model
Bone Metastasis
Model
Intra-cardiac
Model
Lung
Metastasis
Model
•Bone (Metastasis) Model
•Brain Model
•Breast (MFP) Model
•Bladder Model
•Colon Model
•Intra-cardiac (Heart) Model
•Kidney Model
•Liver (Metastasis) Model
•Lung (Metastasis) Model
•Ovary Model
•Pancreas Model
•Prostate Model
•AML (BMI) Model
STRATEGY
1. In House Discovery of Novel Drug
and Diagnostic Marker with PRIINT™
2. Open Assisted Innovation Via
in House Validation Technology
3. Contracted Translational Research
Business: Maximization of Value
Validation in Animal Models by Simulating Clinical Reality
- Clinical Application
(Appropriate Model, Regimen, Unmet Needs, Differentiation)
Join Us
We are always looking for talented people to join us.
Current Openings: Science & Administrative positions
E-mail us at
Contact
Business
Development
Platbio Inc.
E:
T: +82-31-8007-3332
F: +82-31-8007-3363
#1501, Ace GwanggyoTower 2, 91,
Changnyong-daero256beon-gil,
Yeongtong-gu, Suwon-si, Gyeonggi-do,
Republic of Korea 16229
E: